3D Bio-byblos scaffolds

Bio-byblos is a Taiwanese company devoted to the manufacturing of scaffolds and 3D cell culture substrates. Bio-byblos matrices provide a more realistic cell culture environment that allow the interaction between cells.

These scaffolds can be used for the study of the cell metabolism, the investigation of new drugs and the observation of cell behaviour in a growth enviroment similar to the in-vivo conditions. Medical research, drug testing and tissue culture are potential applications of these scaffolds.

Two types of matrices are currently available, Cellusponge and GoMatrix, that can be supplied with different sizes and physical features.

Equipment for Tissue Engineering Research

EBERS Medical Technology is commited to developing general purpose Tissue Engineering flow bioreactors and culture chambers for cell culture and research in Tissue Engineering.

NEW!!! TC-3 mechanical stimulation bioreactor

The new Ttc3_portadaC-3 Bioreactor has been designed as a simple easy-to-use system suitable for cell culture under mechanical loading profiles defined by the user. It has been designed and manufactured thinking of the needs of researcher working on cell culture under mechanical stimuli.

The TC-3 combines the features of a traditional testing machine with the particular demands of cell culture, with special emphasis on the parts sterilization, easy assembling, sample inspection by microscopy techniques and easy manipulation. Also versatility and scalability is a key feature of hte TC-3 in which three grips models can be interchanged in order to adapt to the features of the testing substrate or scaffold.


TEB1000 flow bioreactor

The TEB1000 Master Unit  provides the necessary conditions for cell growing that allow developing cell cultures under accurately controlled flow conditions. The most important advantages of dynamic culture over static culture are the following:

  • Improved nutrient and O2 transport in 3D cultures, specially on those cultures developed on 3D scaffolds
  • Application of controlled mechanical stimulation due to flow action
  • Upregulation of several cell processes

EBERS bioreactors are fully compatible with any other equipment and do not require any additional device to develop the cultures, with the exception of the culture chamber.

    Culture chambers

    Use our vascular chamber to grow cell on tube-shaped scaffolds and the NEW P3D chambers to seed and culture cells on porous scaffolds under perfusion conditions, the simplest way to grow cells on porous scaffolds.

    Product support

    In order to support and improve the use of the P3D chambers, we have developed racks for the P3D chambers which will allow you to culture or seed your scaffols in a simple neat way.

    Dr. Kasper CV

    University of Natural Resources and Applied Life Sciences (BOKU), Vienna, Department of Biotechnology

    Prof. Dr. Cornelia Kasper


    Cornelia Kasper studied Chemistry at the University Hannover and received her Diploma degree 1994. She performed her phD thesis at the Institute for Technical Chemistry 1995-1998 on: “Purification of proteins and other biological active compounds using novel chromatographic approaches”.

    She was employed as EU liason officer at the University of Hannover 1998-2000. Afterwards she received a Habilitation-fellowship from the University of Hannover 2000-2006. She finished her Habilitation on “New approaches in cell culture techniques”and received the Venia legendi “Technische Chemie” in 2007.

    2000-2011 Cornelia Kasper has been head of Cell Culture and Tissue Engineering Group at the Institute for Technical Chemistry, Leibniz University of Hannover. Furthermore she was head of young researcher group JRG “Large Scale Cultivation” within Cluster of Excellence “Rebirth” (from Regenerative Biology and Reconstructive Therapies).

    Since October 2011 Cornelia Kasper has been appointed as full University Professor “Biopharmaceutical Technology and Products” at the Department of Biotechnology at Boku.


    Current Research Activities

    Cells as product – tissue engineering

    • Development of bioreactor systems for tissue engineering applications (including systems for the application of mechanical strain/load)
    • Isolation, expansion and directed differentiation of stem cells from different sources (e.g. fat tissue, umbilical cord)
    • Investigation and optimization of different culture conditions (e.g. hypoxia, medium composition)
    • Isolation and investigation of subpopulations
    • Tissue engineering (musculoskeletal tissues, peripheral nerve) under defined and controlled conditions including biophysical stimulation
    • Establishment of co-culture systems (e.g. MSC and EPC)
    • Functionalization of biomaterials (e.g. surface decoration, incorporation of microspheres as controlled release systems)

    Cells as producers

    • Production and isolation of proteins and growth factors (e.g. FGF, LIF, antibodies)
    • Use of stem cells for production of “natural” cytokines and extracellular matrix proteins

    Cells as sensors

    • Application of cell culture technology for “biological testing” using cell based assays (e.g. biological active compounds, nanoparticles)

    • Study of effects of hydrodynamic forces and mechanotransduction


    EU- Expert for Framework Programme FP 6 and 7 proposals

    Journals (selection):

    • Tissue Engineering
    • Journal of Biotechnology
    • Journal of Tissue Engineering and regenerative Medicine
    • Applied Microbiology and Biotechnology
    • Journal of Biomedical Materials Research


    • Volume Editor “Advances in Biochemical Engineering/ Biotechnology” Springer Verlag
    • Volume 112: “Bioreactors for Tissue Engineering I” (2009)
    • Volume 123: “Bioreactors for Tissue Engineering II” ( 2010)
    • Volume 126: “Tissue Engineering III: Cell Substrate Interaction in Tissue Culture” (2012)
    • In press (two volumes): “Mesenchymal stem cells – from Basics to Clinical Applications” (I + II)

    Membership (selection)

    • DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e. V. (Society for Chemical Engineering and Biotechnology), appointed member of "Cell Culture Technology"
    • ESACT
    • Termis (appointed member of EU chapter counsel)
    • International Society for Cellular Therapy ISCT

    Dr. Cornelia Kasper

    We are very happy to inaugurate our "Interviews with the experts" section with Dr. Kasper, one of the most reputated researchers in TE in Europe. Currently, she is focusing her research in three different lines involving cell culture and holds a the "Biopharmaceutical Technology and Products" full professorship at the University of Boku (Austria).

    A resumed version of Dr. Kasper's CV is available here.


    Interview with the expert

    Dr. Kasper, which difficulties have you had to overcome to start your research programs on tissue engineering?

    One of the major problems was to find suitable inter and transdisciplinary partners/team willing to really work together. Furthermore it was challenging to find a common "language" since the communication in the different research areas and between basic scientists and clinicians for examples differs quite a lot.


    In you experience, which advice would you give to a young researcher starting a career in the field?

    Visit conferences and meetings to gain insight into current research activities and try to get in contact with active researchers. Try to use the special acitivities often offered to suuport young researchers (e.g. SYIS at Termis meeting, summer/winter schools, workshops/trainings)


    It seems that laboratory research has moved considerably more quickly than clinical use of tissue engineering products. What can be done to bring tissue engineering technologies faster to reality? Is it a matter of coordination, focus, funding, lack of technology…?

    Funding is always a bottleneck. But I also think one reason for not having numerous tissue engineering products on market is the lack of understanding and/or harmonization of regulatory issues. Although ATMP guidelines were believed to solve the problems. I think and often see that research is focussed on different areas, technologies are quite advanced, coordination of the activities is often based on EU projects/networks and several developments are close to application/product. The translation of the research results and outcome of clinical studies into market and products is still inhibited by very complex and costly procedures.


    Thus, when will tissue engineering know its real breakthrough? In other words, when will it be applied on a regular basis to help out people?

    I estimate that TE products could be applied within the next 5-8 years. Again, cost reimbursement remains one major issue when it comes to application of TE products in a broader basis. But TE products are much more complex in production and just no therapeutics like Asperin.


    In which the obtaining of funding for research is concerned, what is your opinion on how the system works?

    I can only talk about the fundings systems I experienced so far. But generally I would wish to see funding agencies supporting more young researchers having great and innovative ideas in the future although is might be a lot more risky since the "reputation" of the applicant does not have a long and strong record (this is still one of the main criteria for many reviewer/funding systems).


    Finally, doctors Gordon and Yamanaka have been recently awarded with the Nobel Prize in physiology and medicine for the discovery that mature cells can be reprogrammed to become pluripotent. Do you think it is feasible a Nobel prize for a tissue engineering researcher in the next decade?

    I personally do not believe that pioneers of TE will receive the nobel prize within the next decade.


    Thank you very much Dr. Kasper.